Loading
HS-20093 is an experimental investigational agent whose form is not stated in the registry from Hansoh BioMedical R&D in phase 3 trials for osteosarcoma, non-small-cell lung cancer and sarcomas, with its target not yet stated publicly.
HS-20093 is an investigational agent whose form is not stated in the registry developed by Hansoh BioMedical R&D and Jiangsu HengRui Medicine. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Participants in all subjucts will receive HS-20093 at 10mg/kg. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06935409 (Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure) and NCT06498479 (ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer), in osteosarcoma, non-small-cell lung cancer, sarcomas, prostate cancer and head and neck squamous cell carcinoma. The largest, NCT06498479, plans to enrol 460 participants with primary completion expected 2026-09-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.HS-20093's antibody arm binds its target on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HS-20093" OR ABSTRACT:"HS-20093") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HS-20093, not a curated reading list.
Shares A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer, Jiangsu Hengrui Pharmaceuticals, Prostate cancer and the tag pipeline.
Shares Oesophageal cancer, Sarcomas (soft tissue, bone, GIST), Head and neck squamous cell carcinoma, Prostate cancer and the tag pipeline.
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST), Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Hansoh Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.